Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum September 24, 2025 10:30 AM EDT Company Participants Ryan Crowe - Sen
Regeneron: Looking For Green Shoots Of Growth On Top Of Heartwood Franchises
06:29pm, Tuesday, 23'rd Sep 2025
Regeneron Pharmaceuticals remains a top conviction idea, driven by strong Dupixent growth, a robust pipeline, and a healthy balance sheet. REGN's Q2 earnings showed solid revenue and EPS growth, with
SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU
01:06pm, Monday, 22'nd Sep 2025
Sanofi/Regeneron's Dupixent wins CHMP backing for chronic spontaneous urticaria in the EU, paving the way for expanded treatment options.
Press Release: Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion
12:30am, Monday, 22'nd Sep 2025
Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion Recommendation for adults and adolescents based on phase 3 studies showing Dupixent sig
Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion
12:29am, Monday, 22'nd Sep 2025
Recommendation for adults and adolescents based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo
Regeneron says blood cancer therapy shows 100% response rate in precancerous disorder study
01:23pm, Friday, 19'th Sep 2025
Regeneron said on Friday its experimental therapy showed either a complete or partial disappearance of a precancerous disorder, which manifests into blood cancer, in all patients in a mid-stage trial.
Can Regeneron Change The Paradigm In Multiple Myeloma — And Undercut J&J?
01:15pm, Friday, 19'th Sep 2025
Regeneron unveiled what it calls "paradigm-shifting" test results for a drug that could prevent patients from developing multiple myeloma.
Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks
07:00am, Friday, 19'th Sep 2025
Inmazeb ® (atoltivimab, maftivimab, and odesivimab-ebgn) was the first treatment approved by the U.S. Food and Drug Administration (FDA) for Orthoebolavirus zairense , also known as Zaire ebolavi
Regeneron's bone disorder treatment succeeds in late-stage trial
07:27am, Wednesday, 17'th Sep 2025
Regeneron Pharmaceuticals said on Wednesday its experimental treatment for a rare genetic disorder that affects bone tissue has met the main goal of a late-stage trial.
FOP is a disease in which muscles, tendons and ligaments are progressively replaced by bone, leading to eventual incapacitation
REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock?
10:56am, Monday, 15'th Sep 2025
Regeneron shares slump as Eylea struggles, but Dupixent gains and a strengthening oncology pipeline offer growth potential.
NEW YORK, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C.
Late-breaking data from exploratory analyses at WCLC show Libtayo plus chemotherapy demonstrates a more than double five-year overall survival rate of 19.4%, compared to 8.8% with chemotherapy alone
Regeneron Pharmaceuticals, Inc. (REGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
02:35pm, Monday, 08'th Sep 2025
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 7:00 AM EDT Company Participants Christopher Fenimore - Executive VP of Finance
What's Happening With Regeneron Pharmaceuticals Stock On Monday?
01:11pm, Monday, 08'th Sep 2025
Regeneron Pharmaceuticals, Inc. REGN revealed data from Phase 3 trials in adults with moderate-to-severe cat or birch allergies on Monday. Both trials met their respective primary and key secondary en
